Moneycontrol
Last Updated : Nov 29, 2018 12:28 PM IST | Source: Moneycontrol.com

Cadila Healthcare gains 1% on USFDA nod for Lansoprazole, Linagliptin tablets

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole delayed release orally disintegrating tablets and tentative approval for Linagliptin tablets.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Cadila Healthcare gained 1.5 percent intraday Thursday on the back of USFDA approval to market Lansoprazole delayed release orally disintegrating tablets.

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole delayed release orally disintegrating tablets (US RLD- Prevacid), 15 mg and 30 mg and tentative approval for Linagliptin tablets (US RLD- Tradjenta), 5 mg, as per company release.

Lansoprazole is in a class of drugs called proton pump inhibitors (PPI) which blocks the production of acid by the stomach. Proton pump inhibitors are used for the treatment of conditions such as ulcers, gastroesophageal reflux disease (GERD) and Zollinger—Ellison syndrome that are caused by stomach acid.

Lansoprazole, like other proton-pump inhibitors, blocks the enzyme in the wall of the stomach that produces acid. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 236 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

At 12:22 hrs Cadila Healthcare was quoting at Rs 345.70, up Rs 2.95, or 0.86 percent on the BSE.

For more market news, click here
First Published on Nov 29, 2018 12:28 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant